303 related articles for article (PubMed ID: 25468897)
1. Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy.
Shabanpoor F; McClorey G; Saleh AF; Järver P; Wood MJ; Gait MJ
Nucleic Acids Res; 2015 Jan; 43(1):29-39. PubMed ID: 25468897
[TBL] [Abstract][Full Text] [Related]
2. Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo.
Moulton HM; Fletcher S; Neuman BW; McClorey G; Stein DA; Abes S; Wilton SD; Buchmeier MJ; Lebleu B; Iversen PL
Biochem Soc Trans; 2007 Aug; 35(Pt 4):826-8. PubMed ID: 17635157
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
5. Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.
Blain AM; Greally E; McClorey G; Manzano R; Betts CA; Godfrey C; O'Donovan L; Coursindel T; Gait MJ; Wood MJ; MacGowan GA; Straub VW
PLoS One; 2018; 13(6):e0198897. PubMed ID: 29912990
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
[TBL] [Abstract][Full Text] [Related]
7. Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides.
Tone Y; Mamchaoui K; Tsoumpra MK; Hashimoto Y; Terada R; Maruyama R; Gait MJ; Arzumanov AA; McClorey G; Imamura M; Takeda S; Yokota T; Wood MJA; Mouly V; Aoki Y
Nucleic Acid Ther; 2021 Apr; 31(2):172-181. PubMed ID: 33567244
[TBL] [Abstract][Full Text] [Related]
8. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
9. Cell-penetrating peptides enhance systemic delivery of antisense morpholino oligomers.
Moulton HM
Methods Mol Biol; 2012; 867():407-14. PubMed ID: 22454076
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
[TBL] [Abstract][Full Text] [Related]
11. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
Yin H; Moulton HM; Betts C; Seow Y; Boutilier J; Iverson PL; Wood MJ
Hum Mol Genet; 2009 Nov; 18(22):4405-14. PubMed ID: 19692354
[TBL] [Abstract][Full Text] [Related]
12. Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice.
Desjardins CA; Yao M; Hall J; O'Donnell E; Venkatesan R; Spring S; Wen A; Hsia N; Shen P; Russo R; Lan B; Picariello T; Tang K; Weeden T; Zanotti S; Subramanian R; Ibraghimov-Beskrovnaya O
Nucleic Acids Res; 2022 Nov; 50(20):11401-11414. PubMed ID: 35944903
[TBL] [Abstract][Full Text] [Related]
13. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.
Moulton HM; Moulton JD
Biochim Biophys Acta; 2010 Dec; 1798(12):2296-303. PubMed ID: 20170628
[TBL] [Abstract][Full Text] [Related]
14. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
[TBL] [Abstract][Full Text] [Related]
15. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
16. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
[TBL] [Abstract][Full Text] [Related]
17. mCherry on Top: A Positive Read-Out Cellular Platform for Screening DMD Exon Skipping Xenopeptide-PMO Conjugates.
Lessl AL; Pöhmerer J; Lin Y; Wilk U; Höhn M; Hörterer E; Wagner E; Lächelt U
Bioconjug Chem; 2023 Dec; 34(12):2263-2274. PubMed ID: 37991502
[TBL] [Abstract][Full Text] [Related]
18. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse.
Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Steinhaus JP; Moulton HM; Iversen PL; Wilton SD
Mol Ther; 2007 Sep; 15(9):1587-92. PubMed ID: 17579573
[TBL] [Abstract][Full Text] [Related]
19. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
Negishi Y; Ishii Y; Nirasawa K; Sasaki E; Endo-Takahashi Y; Suzuki R; Maruyama K
Methods Mol Biol; 2018; 1687():185-192. PubMed ID: 29067664
[TBL] [Abstract][Full Text] [Related]
20. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]